Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference34 articles.
1. Vermeer NS, Straus SMJM, Mantel-Teeuwisse AK, Domergue F, Egberts TCG, Leufkens HGM, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Saf. 2013;36(8):617–25.
2. US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015.
https://www.fda.gov/media/82647/download
. Accessed 28 June 2019.
3. Jancin B. Industry-funded rheumatology RCTs are higher quality. Rheumatology news. 2019.
https://www.mdedge.com/rheumatology/article/197008/psoriatic-arthritis/industry-funded-rheumatology-rcts-are-higher-quality
. Accessed 20 May 2019.
4. Trifirò G, Gini R, Barone-Adesi F, Beghi E, Cantarutti A, Capuano A, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347–63.
https://doi.org/10.1007/s40264-018-0732-5
.
5. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233–43.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献